04.12.18|CTechRedHill’s new pill managed to eradicate 84% of H. pylori bacteria, as opposed to 58% in patients receiving the standard of care
12.08.18|Dror ReichThe gastro treatment company announced a successful Crohn's disease treatment trial two weeks ago. While investors initially seemed hyped, successful trials from competitors brought RedHill’s stock down since
24.07.18|Lilach BaumerThe Tel Aviv-headquartered company announced on Monday that Nasdaq approved its listing on its second tier, the Global Market. RedHill's ADSs were previously listed on Nasdaq Capital Market
01.10.17|Lilach BaumerIsrael-based Colospan develops a device that prevents inner-body leaks after intestinal surgery